在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

Phospho-PTPN11 (Y542) Recombinant Monoclonal Antibody

  • 中文名稱:
    磷酸化-PTPN11 (Y542)重組抗體
  • 貨號:
    CSB-RA019025A542phHU
  • 規格:
    ¥1320
  • 圖片:
    • Western Blot
      Positive WB detected in Hela whole cell lysate, 293 whole cell lysate, A549 whole cell lysate(treated with Pervanadate or not)
      All lanes Phospho-PTPN11 antibody at 0.65μg/ml
      Secondary
      Goat polyclonal to rabbit IgG at 1/50000 dilution
      Predicted band size: 68 KDa
      Observed band size: 68 KDa
    • Immunoprecipitating Phospho-PTPN11 in Hela whole cell lysate treated with Pervanadate
      Lane 1: Rabbit control IgG(1μg)instead of CSB-RA019025A542phHU in Hela whole cell lysate treated with Pervanadate. For western blotting,a HRP-conjugated Protein G antibody was used as the secondary antibody (1/2000)
      Lane 2: CSB-RA019025A542phHU(3μg)+ Hela whole cell lysate treated with Pervanadate(1mg)
      Lane 3: Hela whole cell lysate treated with Pervanadate(20μg)
  • 其他:

產品詳情

  • 產品描述:
    CSB-RA019025A542phHU重組單克隆抗體是針對磷酸化修飾位點PTPN11-Y542的高特異性科研工具。PTPN11編碼的SHP-2蛋白是一種非受體型蛋白酪氨酸磷酸酶,通過調控RAS/MAPK等信號通路參與細胞增殖、分化及免疫應答,其Y542位點的磷酸化狀態直接影響酶活性與下游信號傳遞,在腫瘤發生和發育異常中具有重要研究價值。該抗體經多種技術平臺驗證,在Western Blot中可特異性識別內源性磷酸化PTPN11蛋白,IP實驗證實其能有效富集目標蛋白復合物,ELISA分析顯示其對靶標表位具有高親和力。推薦使用濃度范圍為WB 1:500-1:5000、IP 1:200-1:1000,適用于探究SHP-2磷酸化修飾在細胞信號轉導、腫瘤微環境調控以及發育生物學中的分子機制。作為重組單克隆抗體,其具備優異的批次間穩定性,可滿足磷酸化蛋白動態監測、蛋白互作研究及通路抑制劑篩選等基礎科研需求,為探索酪氨酸磷酸酶家族在疾病相關通路中的作用提供可靠工具。
  • Uniprot No.:
  • 基因名:
  • 別名:
    BPTP3 antibody; CFC antibody; JMML antibody; METCDS antibody; MGC14433 antibody; NS1 antibody; OTTHUMP00000166107 antibody; OTTHUMP00000166108 antibody; Protein tyrosine phosphatase 2 antibody; Protein tyrosine phosphatase 2C antibody; Protein tyrosine phosphatase non receptor type 11 antibody; Protein-tyrosine phosphatase 1D antibody; Protein-tyrosine phosphatase 2C antibody; PTN11_HUMAN antibody; PTP-1D antibody; PTP-2C antibody; PTP1D antibody; PTP2C antibody; PTPN11 antibody; SAP2 antibody; SH-PTP2 antibody; SH-PTP3 antibody; SH2 domain containing protein tyrosine phosphatase 2 antibody; SHP 2 antibody; SHP-2 antibody; Shp2 antibody; SHPTP2 antibody; SHPTP3 antibody; Syp antibody; Tyrosine-protein phosphatase non-receptor type 11 antibody
  • 反應種屬:
    Human
  • 免疫原:
    A synthesized peptide derived from Human Phospho-PTPN11 (Y542)
  • 免疫原種屬:
    Homo sapiens (Human)
  • 標記方式:
    Non-conjugated
  • 克隆類型:
    Monoclonal
  • 抗體亞型:
    Rabbit IgG
  • 純化方式:
    Affinity-chromatography
  • 克隆號:
    2E2
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液:
    Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
  • 產品提供形式:
    Liquid
  • 應用范圍:
    ELISA, WB, IP
  • 推薦稀釋比:
    Application Recommended Dilution
    WB 1:500-1:5000
    IP 1:200-1:1000
  • Protocols:
  • 儲存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期:
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途:
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

  • 功能:
    Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. Positively regulates MAPK signal transduction pathway. Dephosphorylates GAB1, ARHGAP35 and EGFR. Dephosphorylates ROCK2 at 'Tyr-722' resulting in stimulation of its RhoA binding activity. Dephosphorylates CDC73. Dephosphorylates SOX9 on tyrosine residues, leading to inactivate SOX9 and promote ossification.
  • 基因功能參考文獻:
    1. Genetic or pharmacologic inactivation of SHP2 promotes accumulation of JAK2 phosphorylated at Y570, reduces JAK2/STAT3 signaling, inhibits TGFbeta-induced fibroblast activation and ameliorates dermal and pulmonary fibrosis. PMID: 30108215
    2. Authors identify that miR-186 serves as a tumor suppressor in OSCC. Downregulation of this microRNA may lead to a higher expression of oncogenic factor SHP2, which leads to activation of growth promoting signaling. PMID: 29407635
    3. REVIEW: structural basis and recent research progression on SHP2 in various human disease, including genetic and cancer diseases. PMID: 27028808
    4. the tumor promoting role of YAP is involved in SHP2 which functions as a tumor promoter in vitro but as a tumor suppressor in vivo PMID: 29699904
    5. Data indicate that by inhibiting adenine nucleotide translocase 1 (ANT1) and mitochondrial dysfunction, tyrosine phosphatase SHP2 orchestrates an intrinsic regulatory loop to limit excessive NLR family, pyrin domain-containing 3 protein (NLRP3) inflammasome activation. PMID: 29255148
    6. Findings revealed that SHP2 is associated with cisplatin-induced drug resistance in lung cancer and directly activates Ras, which in turn regulates the PI3K/Akt pathway. PMID: 29207183
    7. SHP-2 is activated by CD16b crosslinking in neutrophils. PMID: 29137913
    8. Proliferation and soft agar assays were used to demonstrate the functional contribution of SHP2 to cell growth and transformation. SHP2 expression correlated with SOX2 expression in glioma stem cell (GSC) lines and was decreased in differentiated cells. Forced differentiation of GSCs by removal of growth factors, as confirmed by loss of SOX2 expression, also resulted in decreased SHP2 expression. PMID: 28852935
    9. PTPN11 plays a role in regulating neurotrophin protective signaling in neuronal cells; PTPN11 dysregulation promotes apoptotic activation. PMID: 28947394
    10. This study provides information on phenotypes observed in Noonan syndrome patients with different PTPN11 mutations and defines two novel mutations. PMID: 26817465
    11. SHP-2 protein may become a new target for anti-malignant transformation of glioma. PMID: 28620155
    12. High SHP2 expression is associated with colorectal tumors. PMID: 27582544
    13. SHP2 expression was activated by the HBx-NF-kappaB pathway. In patients with HCC, a loss of SHP2 expression was associated with suppressed NF-kappaB-SHP2-ERK pathway activity and accelerated HCC development, whereas SHP2 overexpression in parallel with increased STAT3 activity was associated with fibrosis promotion during the early stages of HCC development. PMID: 28460481
    14. The inhibitory action of cryptotanshinone is largely attributed to the inhibition of STAT3 Tyr705 phosphorylation with a novel mechanism of upregulating the tyrosine phosphatase activity of SHP-2 protein. PMID: 28492557
    15. Studies indicate that multiple classes of PTPN11 mutations with a distinct perturbing effect on SHP2's function. PMID: 28074573
    16. Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia. PMID: 28853218
    17. Studied mutations of PTPN11 in a cohort of Noonan Syndrome patients. Mutational analysis was performed and PTPN11 mutations were detected in 11 out of 17 (64.7%) patients with Noonan syndrome; 72% had mutation in exon 3 and 27 % had mutation in exon 13. PMID: 28607217
    18. NO controls the calcium signal propagation through Cx37-containing gap junctions. The tyrosine phosphatase SHP-2 is the essential mediator and NO target. PMID: 29025706
    19. we describe patients with craniosynostosis and Noonan syndrome due to de novo mutations in PTPN11 and patients with craniosynostosis and CFC syndrome due to de novo mutations in BRAF or KRAS. All of these patients had cranial deformities in addition to the typical phenotypes of CFC syndrome and Noonan syndrome. PMID: 28650561
    20. These results suggest that SHP-2-via association with ICAM-1-mediates ICAM-1-induced Src activation and modulates VE-cadherin switching association with ICAM-1 or actin, thereby negatively regulating neutrophil adhesion to endothelial cells and enhancing their transendothelial migration. PMID: 28701303
    21. High PTPN11 expression is associated with suppression of T lymphocyte function in Melanoma. PMID: 27930879
    22. PTPN11 mutations are the most common cause of the Noonan syndrome, along with frequent neuroepithelial brain tumors. (Review) PMID: 28328117
    23. A novel PTPN11 mutation defined in two separate fetuses with Cystic hygroma and associated with Noonan syndrome phenotype is being reported. PMID: 27193571
    24. High PTPN11 expression is associated with Pancreatic cancer. PMID: 27213290
    25. SHP-2 acts together with PI3K/AKT to regulate a ZEB1-miR-200 feedback loop in PDGFRalpha-driven gliomas. PMID: 27041571
    26. The data presented in the current study reveal that intestinal serotonin transporter (SERT) is a target of the tyrosine phosphatase SHP2 and show a novel mechanism by which a common diarrheagenic pathogen, EPEC, activates cellular SHP2 to inhibit SERT function. PMID: 28209599
    27. The effects of SHP2 overexpression and inhibition on fibroblast response to profibrotic stimuli were analyzed in in primary human fibroblasts. SHP2 was down-regulated and lung fibroblasts obtained from patients with IPF, revealing SHP2 was absent within fibroblastic foci sufficient to induce fibroblast-to-myofibroblast differentiation in primary human lung fibroblasts, resulting in reduced cell survival. PMID: 27736153
    28. PTPN11 variant was identified in a case with a lethal presentation of Noonan syndrome. PMID: 28098151
    29. Appropriate knowledge of the phenotype-genotype correlations and of the outcome of cochlear implantation in genetic hearing impairment is important in the work-up to a CI PMID: 28483241
    30. our results provide strong evidence that CD244 co-operates with c-Kit to regulate leukemogenesis through SHP-2/p27 signaling. PMID: 28126968
    31. SHP2, SOCS3 and PIAS3 levels are reduced in medulloblastomas in vivo and in vitro, of which PIAS3 downregulation is more reversely correlated with STAT3 activation. In resveratrol-suppressed medulloblastoma cells with STAT3 downregulation and decreased incidence of STAT3 nuclear translocation, PIAS3 is upregulated, the SHP2 level remains unchanged and SOCS3 is downregulated. PMID: 28035977
    32. could promote hepatocellular carcinoma cell dedifferentiation and liver cancer stem cell expansion by amplifying beta-catenin signaling PMID: 28059452
    33. The results revealed that although the expression levels of SOCS1, SOCS3 and, in particular, pSHP2, tend to decrease in the four types of astrocytomas, PIAS3 downregulation is more negatively correlated with STAT3 activation in the stepwise progress of astrocytomas and would indicate an unfavorable outcome. PMID: 28035384
    34. In a retroviral transduction/transplantation mouse model, mice transplanted with MLL/AF10(OM-LZ) cells harboring PTPN11(wt) developed myelomonocytic leukemia. Those transplanted with cells harboring PTPN11(G503A) -induced monocytic leukemia in a shorter latency. Adding PTPN11(G503A) to MLL/AF10 affected cell proliferation, chemo-resistance, differentiation, in vivo BM recruitment/clonal expansion and faster progression. PMID: 27859216
    35. Shp2 (Src-homology 2 domain-containing phosphatase 2) functions as a negative regulator for STAT3 transcription factor (Stat3) activation in esophageal squamous cell cancer (ESCC). PMID: 28085101
    36. the phosphatase activity of Shp2 and its tyrosine phosphorylation, are necessary for the IL-6-induced downregulation of E-cadherin and the phosphorylation of Erk1/2. Our findings uncover an important function that links Shp2 to IL-6-promoted breast cancer progression. PMID: 28208810
    37. This study reveals the critical contribution of Ptpn11 mutations in the bone marrow microenvironment to leukaemogenesis and identifies CCL3 as a potential therapeutic target for controlling leukaemic progression in Noonan syndrome and for improving stem cell transplantation therapy in Noonan-syndrome-associated leukaemias. PMID: 27783593
    38. higher expression of SHP2 might be involved in the progression of pancreatic ductal adenocarcinoma, suggesting that SHP2 may be a potential prognostic marker and target for therapy PMID: 26695153
    39. Data indicate that the most prominent proteins associating with Gab2 are PTPN11, PIK3R1 and ARID3B. PMID: 27025927
    40. Since rs2301756 polymorphism of PTPN11 was associated with reduced risk of gastric cancer and better effects of chemotherapy on gastric cancer, it can be considered as a predictor of gastric cancer prognosis and the treatment target for gastric cancer. PMID: 27614952
    41. SHP2 gain-of-function mutation enhances malignancy of breast carcinoma. PMID: 26673822
    42. mutation in PTPN11 is associated with co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome. PMID: 26286251
    43. The existence of a tight association between SHP2 and EGFR expression in tumors and cell lines further suggested the importance of SHP2 in EGFR expression. PMID: 26728598
    44. patients with low Shp2 expression exhibited superior prognosis to sorafenib PMID: 25865556
    45. Combined X-ray crystallography, small-angle X-ray scattering, and biochemistry to elucidate structural and mechanistic features of three cancer-associated SHP2 variants with single point mutations within the N-SH2:PTP interdomain autoinhibitory interface. PMID: 27030275
    46. In vitro assays suggested that LEOPARD syndrome-associated SHP-2 mutations might enhance melanin synthesis in melanocytes, and that the activation of Akt/mTOR signalling may contribute to this process. PMID: 25917897
    47. SHP2 may promote invadopodia formation through inhibition of Rho signaling in cancer cells. PMID: 26204488
    48. Shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition PMID: 26050620
    49. PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs. PMID: 26365186
    50. SHP2 preferentially binds to and dephosphorylates Ras to increase its association with Raf and activate downstream proliferative Ras/ERK/MAPK signaling. PMID: 26617336

    顯示更多

    收起更多

  • 相關疾?。?/div>
    LEOPARD syndrome 1 (LPRD1); Noonan syndrome 1 (NS1); Leukemia, juvenile myelomonocytic (JMML); Metachondromatosis (MC)
  • 亞細胞定位:
    Cytoplasm. Nucleus.
  • 蛋白家族:
    Protein-tyrosine phosphatase family, Non-receptor class 2 subfamily
  • 組織特異性:
    Widely expressed, with highest levels in heart, brain, and skeletal muscle.
  • 數據庫鏈接:

    HGNC: 9644

    OMIM: 151100

    KEGG: hsa:5781

    STRING: 9606.ENSP00000340944

    UniGene: Hs.506852



主站蜘蛛池模板: 制服 丝袜 人妻 专区一本| 亚洲第一天堂无码专区| 欧美综合区自拍亚洲综合绿色 | 欧美精品久久久久久久自慰| 国产精品欧美福利久久| 免费无码av片在线观看网址| 97丨九色丨国产人妻熟女| 黑森林福利视频导航| 国产亚洲欧美另类一区二区 | 玩弄丰满少妇人妻视频| 亚洲成av人片在线观看无码 | 国产乱子经典视频在线观看| 国产精品高潮露脸在线观看| 国产在线拍揄自揄视频导航| 在线亚洲97se亚洲综合在线| 一区二区在线 | 国| 亚洲人成伊人成综合网久久久| 亚洲精品美女久久7777777| 野花社区在线www日本| 男人吃奶摸下挵进去好爽| 国产草草影院ccyycom| 亚洲精品白浆高清久久久久久| 在线播放十八禁视频无遮挡| 国产免费又色又爽又黄软件| 免费乱码人妻系列无码专区| 激情五月综合色婷婷一区二区| 一本色道av久久精品+网站| 久久久亚洲精品av无码| 亚洲精品中文字幕无码蜜桃| 国产成人vr精品a视频| 99久久无码一区人妻a黑 | 色先锋影音岛国av资源| 伊人久久大香线焦av综合影院| а天堂中文官网| 狠狠精品久久久无码中文字幕| 国产真实乱对白精彩久久| 2021国产精品自在自线| 亚洲欧美日韩成人综合一区| 国产放荡对白视频在线观看| 18禁止看的免费污网站| 国产成人免费97在线观看|